Several lines of evidence suggest that neuregulin 1 (NRG1) signaling may influence cognitive function and neuropathology in Alzheimer’s disease (AD). To test this possibility, full-length type I or type III NRG1 was overexpressed via lentiviral vectors in the hippocampus of line 41 AD mouse. Both type I and type III NRG1 improves deficits in the Morris water-maze behavioral task. Neuropathology was also significantly ameliorated. Decreased expression of the neuronal marker MAP2 and synaptic markers PSD95 and synaptophysin in AD mice was significantly reversed. Levels of Aβ peptides and plaques were markedly reduced. Furthermore, we showed that soluble ectodomains of both type I and type III NRG1 significantly increased expression of Aβ-degrading enzyme neprilysin (NEP) in primary neuronal cultures. Consistent with this finding, immunoreactivity of NEP was increased in the hippocampus of AD mice. These results suggest that NRG1 provides beneficial effects in candidate neuropathologic substrates of AD and, therefore, is a potential target for the treatment of AD.
Alzheimer’s Disease (AD) is characterized by the degeneration of neurons in the hippocampus and cortex and the appearance of neuritic plaques and neurofibrillary tangles1,2,3. Although the precise cause of AD remains unclear and is in fact most likely from multiple etiologies. Aggregated Aβ-peptides, resulting from proteolytic cleavage of the amyloid precursor protein (APP), constitute a prime neurotoxic component of senile plaques in the brains of AD patients. Several therapeutic approaches are aimed at reducing Aβ load and neutralizing Aβ toxicity, including passive immunization with Aβ4,5, preventing aggregation of Aβ6, inhibiting Aβ production using β- and γ-secretase inhibitors or siRNA7, increasing levels of Aβ-degrading enzymes such as Neprilysin (NEP)8, insulin-degrading enzyme9 or cathepsin10 and augmenting anti-oxidation capacity. Over the past several years, a consensus has emerged that a cocktail of drugs influencing multiple mechanisms may be required to effectively treat AD.
Through alternative splicing of the neuregulin 1 (NRG1) primary mRNA transcript, several subtypes are produced as transmembrane (TM) precursor proteins11. Type I (also called neu differentiation factor and acetylcholine receptor-inducing activity) and type II (glial growth factor) NRG1 isoforms contain an Ig domain and an epidermal growth factor (EGF)-like domain, but differ by the presence of a Kringle domain in type II NRG1. Proteolytic cleavage in the extracellular domain near the TM domain of type I and type II NRG1s yields soluble ligands that activate ErbB receptors. Type III (sensory and motor neuron-derived factor) NRG1 isoforms contain an EGF-like domain and a unique cysteine-rich domain that is postulated to serve as a secondary TM domain. Recent evidence suggests that dual cleavage of type III NRG1 by BACE1 and ADAM17 liberates its EGF-like domain and permits paracrine signaling12. NRG1 and its cognate receptor ErbB2/ErbB3 and ErbB2/ErbB4 heterodimers or ErbB4 homodimers mediate diverse signaling pathways in neural development and function13.
Several lines of evidence suggest that NRG1 itself, or manipulation of NRG1 signaling, may influence cognitive function and neuropathology in AD. First, a single nucleotide polymorphism (SNP) of the NRG1 gene (rs392499) previously found in schizophrenia families is associated with late onset AD with psychosis in U.S. patients14. Interestingly, NRG3, another member of the NRG family15, is associated with the risk and age at onset of AD16. Second, expression of erbB1-4 is altered in mouse models of AD17,18,19. Third, type I NRG1 down-regulates and increases turnover of APP in C2C12 cells20. Fourth, NRG1 is neuroprotective against focal cerebral ischemia21 and prevents PC12 cell death induced by Aβ22. Finally, Aβ reduces spine density23, whereas NRG1 signaling maintains spine morphology and density24. Collectively, these data suggest that NRG1 signaling may influence Aβ load, synaptic integrity, neuroprotection and cognitive function in AD.
In the present study, we showed that overexpression of either type I or type III NRG1 improves cognitive deficits and ameliorates neuropathology in AD mice25. Furthermore, we showed that NRG 1 significantly increases the expression of NEP in neuronal cultures. These results suggest that NRG1 is a potential target for the treatment of AD.
NRG1 improves deficits in Morris water maze behavioral test
To test whether exogenous NRG1 improves congnitive function in AD post-symptomatically, control lentiviruses (LV-control) and lentiviruses expressing full-length rat β1α NRG1 type I (LV-NRG1/I) or type III (LV-NRG1/III) under the CMV promoter were generated and stereotaxically injected into the hippocampus of 7-month old female line 41 transgenic mice expressing a mutated human APP (APP-Tg)25 and female non-TG control littermates. Eight weeks after viral injection, performance in the Morris water maze was evaluated. Latency to find the escape platform (Fig. 1A) and distance traveled (Fig. 1B) during the visible and hidden platform phases were measured. The means of latency or distance across all four trials daily from days 1–3 for visible platform and from days 4–7 for hidden platform were calcuated26. Differences among means of the six groups were assessed by repeated measures ANOVA followed by Fisher’s least significant difference post-hoc test with level of significance set at p < 0.05. Post-hoc analyses revealed that APP-Tg controls were significantly delayed in finding the escape platform compared to the APP-Tg group injected with type I or type III NRG1 and non-Tg littermates injected with LV-control during the visible platform phase of learning. During the hidden platform phase, the APP-Tg group injected with LV-NRG1/I showed a statistically significant improvement in latency and distance compared to the APP-Tg group injected with the LV-control (Fig. 1C,D). The APP-Tg group injected with NRG1 type III showed a trend of improvement compared with the APP-Tg controls. Distance traveled was also higher in the APP-Tg controls compared to all other groups, consistent with an increase in latency with actively searching for the escape platform. These results support that both type I and type III NRG1s can restore behavioral deficits in the Morris water maze task in the line 41 AD model.
Aβ load is decreased by type I and type III NRG1
We determined whether expression of exogenous NRG1 is elevated following bilateral viral injection into the hippocampus of non-Tg and APP-Tg mice. Levels of endogenous NRG1 protein in the brain showed no differences between Non-Tg and TG (Supplemental Figure S1). Following viral injection, levels of NRG1 protein were 2-fold higher in mice injected with LV-NRG1/I or LV-NRG1/III LV than those in controls (Fig. 2A,B). Furthermore, levels of phosphorylation of ErbB4 in LV-NRG1 were 2.5 fold higher than those in LV-control (Fig. 2C,D), supporting activation of ErbB4-mediated signaling pathways. Immunostaining shows that the majority of cells being transduced are MAP2-positive pyramidal neurons, though a small percentage of GFAP–positive astrocytes were also transduced (Fig. 3).
To determine whether elevated levels of NRG1 affect Aβ load, brain sections were immunostained with antibodies specifically detecting human Aβ (Fig. 4A). To quantify amyloid deposition, the area of neuropil occupied by Aβ-immunoreactivity was calculated from 9 randomly selected sections per mouse. Type I and type III NRG1s decreased amyloid deposition by 37% and 66% compared to control viruses, respectively (Fig. 4B). Consistent with this finding, levels of Aβ were markedly reduced in the APP-Tg injected with LV-NRG1/I or LV-NRG1/III, though levels of APP were not altered (Fig. 4C,D). These results indicate that both type I and type III NRG1s can reduce Aβ load in the line 41 AD mouse model.
Neuropathology is ameliorated by type I and type III NRG1
Aβ neurotoxicity is known to affect multiple compartments of neurons, including dendrites and synapses. To determine whether type I or type III NRG1 reduces dendritic and synaptic alterations in APP-Tg mice, immunohistochemistry and Western blotting analysis were performed. As shown in Fig. 5A, MAP2 immunoreactivity is markedly reduced in APP-Tg mice as compared to that in non-Tg controls. The reduction is ameliorated by both type I and type III NRG1s (Fig. 5A). Similarly, a reduction in the presynaptic marker, synaptophysin, was observed in the APP- Tg mice (Fig. 5B,C). The alteration was reversed by both type I and type III NRG1 (Fig. 5B,C). Consistent with immunohistochemical analysis, Western blotting analysis confirmed that levels of synaptophysin in mice injected with type I or type III NRG1 were comparable to those in non-Tg controls (Fig. 5D,E). When the postsynaptic marker, PSD95, was analyzed, similar results were observed (Fig. 5E). These results demonstrated that neuropathology in AD mice was ameliorated by both type I and type III NRG1.
Type I and type III NRG1 increase expression of Aβ-degrading enzyme Neprilysin
Because Aβ load was decreased by both type I and type III NRG1, we next sought to examine potential mechanisms underlying the effects of NRG1 overexpression on amyloid plaque numbers. Several lines of evidence led us to examine whether NRG1, acting through ErbB receptors, induces expression or activity of the NEP. First, NEP is one of the most potent Aβ-degrading enzymes27. Second, NRG1 promotes muscle regeneration28 and NEP is also expressed and implicated in muscle regeneration29. Immunostaining shows that the immunoreactivity of NEP was dramatically increased in mouse brains injected with LV-NRG1/I or LV-NRG1/III (Fig. 6A,B). Next, we sought to study if NRG1 can regulate NEP expression in vitro. We demonstrated that levels of NEP were elevated in primary hippocampal neurons treated with 50 ng/ml soluble recombinant type I human NRG1 or type III NRG1 (Fig. 6C,D) for 48 hours. These results indicate that the soluble ectodomains of both type I and type III NRG1 are able to increase expression of NEP with comparable potency. To gain mechanistic insights into NRG1-regulated NEP expression, a luciferase reporter construct containing a 2.5 kb human NEP promoter30 was transfected into NB7 cells, which express endogenous NEP (data not shown). The results showed that both soluble type I and type III NRG1s significantly stimulate NEP promoter activity (Supplemental Figure S2). These results suggest that NRG1 increases NEP expression in part through transcriptional activation of the NEP promoter.
In the present study, we demonstrate that exogenous NRG1 improves deficits in Morris water maze behavioral task and neuropathology in a mouse line 41 model of AD. Aβ load is markedly reduced. Consistent with these results, solube ectodomains of both type I and type III NRG1s induce expression of Aβ-degradading enzyme NEP in primary hippocampal neuronal cultures. Our results suggest that NRG1 is a therapeutic target for the treatment of AD, but additional studies are needed before devising the strategy of using NRG1 itself or agents modulating NRG1-mediated signaling pathways for therapeutic purposes.
In addition to increasing NEP expression, NRG1 may improve deficits in AD mice via other mechanisms. NRG1 signaling has been shown to play a role in synaptic differentiation and function in the CNS. For example, NRG1 increases dendritic spine size24, modulates long-term potentiation at CA1 synapses31,32,33 and enhances entorhinal-hippocampal synaptic transmission34. NRG1 enhances depolarization-induced GABA release in the prefrontal cortex35. NRG1 also modulates hippocampal gamma oscillations36 that are thought to synchronize neuronal networks during learning and memory. Interestingly, recent results demonstrate that deficits in inhibitory interneurons link altered network activity and cognitive dysfunction in an AD model37,38. Therefore, further investigation is needed to determine if elevated expression of NRG1 modulates synaptic function in APP-Tg. Furthermore, ErbB4 is expressed in interneurons39, whereas ErbB2 and ErbB3 receptors are expressed in glial cells. Thus, NRG1 may affect neuronal structure and function by indirectly regulating the function of glia40.
While our results support beneficial effects of NRG1, transgenic overexpression of full length type I or type III NRG1 impairs cortical functions41,42. The discrepancy may be due to differences in approaches. The transgenic approach is different from lentivirus-mediated transduction utilized in our study in terms of the timing, brain regions and levels of NRG1 overexpression. For example, in Agarwal et al. expression levels of type III NRG1 were four-fold higher relative to controls in the whole brain starting from the E16 stage and onwards. Thus, the timing and the target cell populations of NRG1 overexpression are quite different from our paradigm of lentivirus transduction in the hippocampus of adult mice. Similarly, in Yin et al. NRG1 type I was selectively increased under the control of the CamK2α promoter in excitatory neurons in multiple forebrain regions, including the prefrontal cortex, the hippocampal and the striatum. Furthermore, overexpression of exogenous NRG1 starts at neonatal stages. Finally, when expressed at modest levels, NEP has been shown to afford beneficial effects in AD mice8,43,44,45. It is worth noting that much higher levels of NEP are implicated in side effects in vivo likely due to non-specific activity of NEP on other targets46.
The human mutant APP transgenic mouse is an imperfect AD model47. For example, it contains multiple copies of mutated human APP cDNA under the control of artificial promoters that may not recapitulate the dysregulated expression patterns in vivo. In addition to elevated levels of Aβ, the resulting high levels of APP and other processed APP fragments may cause unexpected effects47. To circumvent this problem, Saito et al. generated a single humanized APP mutation knock-in AD mouse model47. Hence, it warrants future testing of NRG1 treatment in other AD models, including the single humanized APP mutation knock-in AD mouse model47 and the triple transgenic mice that display both plaque and tangle pathology48. Furthermore, in contrast to the finding of a positive correlation of SNP rs392499 in U.S. AD patients14, there is no such a correlation in U.K. AD patients49. Middle et al. suggest that the discrepancy may be due to several differences in both studies, including the design on selection of cohorts and haplotype analysis programs. As there are additional SNPs, an in-depth analysis of other variants needs to be performed with the same experimental design.
Finally, as peripheral delivery of soluble NRG1 has been shown to be capable of crossing the blood brain barrier (BBB)50,51, the results raise the possibility of devising a strategy for an enhanced ability to cross the BBB52 and for a regulated delivery of NRG1 from a peripheral tissue such as muscle. Taken together, these and our studies add valuable information in considering how to control spatiotemporal regulation and expression levels of exogenous NRG1 as a treatment for AD.
Antibodies include monoclonal antibody against NEP (clone Ab951) and PSD95 (Abcam), rabbit polyclonal antibody against NRG1 (clone SC-348) and anti-ErbB4 (Santa Cruz), anti-phospho-ErbB4 (Tyr1284) (Cell Signaling), mouse anti-β-actin antibody (Sigma), mouse monoclonal Aβ antibody 6E10 (Covance) and synaptophysin (Millipore).
Recombinant soluble Neuregulin 1 and NRG1-expressing lentiviral vectors
Recombinant soluble human type I NRG1 (NDFβ114-246) was obtained from Amgen (Thousand Oaks, CA). Recombinant human type III NRG1 (SMDF, catalogue # 378-SM-025) was purchased from R&D systems (Minneapolis, MN). Lentiviruses expressing rat β1, a full length type I or type III NRG153 under the CMV promoter, were generated using the ViraPower Lentiviral Expression System (Invitrogen) and were produced by the Gene Transfer Core at the Salk Institute.
Animals and Viral injection
Transgenic mice line 41 expressing hAPP751 cDNA containing the London (V717I) and Swedish (K670M/N671L) mutations under the regulatory control of the murine Thy-1 gene was reported previously25. The increased Aβ plaque burden was found in the cortex and hippocampus starting at three to four months in this line 41 transgenic mouse25. These mice already show significant learning and memory deficits in the Morris water maze by six months of age54. To investigate if exogenous NRG1 can improve cognitive impairment and ameliorate neuropathology post-symptomatically, 7- month old APP-Tg and age-matched control littermates were divided into 6 groups (N = 6) and received bilateral injections of LV-control, LV-NRG1/I or LV-NRG1/III, respectively. To avoid any compounding factors associated with sex, only female non-Tg and APP-Tg mice were included. Stereotaxic injection was performed using a Hamilton syringe connected to a hydraulic system at 1 μl every 2 min. A total 2 μl of lentivirus was infused into each hippocampus. The needle was left in place for 5 min after completion of injection. Coordinates for viral injection of the hippocampus are (AP-2, ML ± 1.5 and DV-1.3). All experiments described were carried out in strict accordance with good animal practice according to NIH recommendations. All procedures for animal use were approved by the Institutional Animal Care and Use Committee at the Salk Institute.
Water maze test
The water maze test was performed as previously described26,44. For this purpose, a pool (diameter 180 cm) was filled with opaque water (24 °C) and mice were first trained to locate a visible platform (days 1–3) and then a submerged hidden platform (days 4–7) in four daily trials 2–3 min apart. Mice that failed to find the hidden platform within 90 seconds were placed on it for 30 seconds. The same platform location was used for all sessions and all mice. The starting point at which each mouse was placed in the water was changed randomly between two alternative entry points located at a similar distance from the platform. Time to reach the platform (latency), path length and swim speed were recorded with a Noldus Instruments EthoVision video tracking system (San Diego Instruments) set to analyze two samples per second. The data were calculated by a method previously described26. The means of latency or distance across all four trials daily from day 1 to day 3 for visible platform and from day 4 to day 7 for hidden platform were calcuated. Repeated measures ANOVA followed by Fisher’s Least Significant Difference post-hoc test was used in the analyses with level of significance set at p < 0.05. A two-tailed Student t-test was utilized where appropriate, with calculated comparisons of p < 0.05 considered significant. All reported values represent the means ± standard error of the mean (SEM).
Analysis of NEP expression and neurodegeneration
To verify the expression levels of NEP, vibratome sections were immunolabeled with a monoclonal antibody against NEP (CD10, Abcam) and detected with the Tyramide Signal AmplificationTM-Direct (Red) system (NEN Life Sciences). All sections were processed simultaneously under the same conditions and immunostaining procedures were performed twice to assess reproducibility. Sections were imaged with a Zeiss 63X (N.A. 1.4) objective on an Axiovert 35 microscope (Zeiss) with an attached MRC1024 LSCM system (BioRad). To confirm the specificity of primary antibodies, control experiments were performed where sections were incubated overnight in the absence of primary antibody (deleted) or preimmune serum and primary antibody alone. The integrity of the neuronal structure was evaluated as previously described54,55; briefly, blind-coded, 40 μm thick vibratome sections from mouse brains fixed in 4% paraformaldehyde were immunolabeled with the mouse monoclonal antibodies against MAP2 (dendritic marker), synaptophysin (presynaptic marker, Millipore) and PSD95 (postsynaptic marker, Abcam). After overnight incubation, sections were incubated with the Tyramide Signal Amplification TM-Direct (Red) system (NEN Life Sciences), transferred to SuperFrost slides (Fisher Scientific) and mounted under glass coverslips with anti-fading media (Vector Laboratories). All sections were processed under the same standardized conditions. The immunolabeled blind-coded sections were serially imaged with the LSCM (MRC1024, BioRad) and analyzed with the ImageJ 1.43 program (NIH), as previously described8. For each mouse, a total of 3 sections were analyzed and for each section, 4 fields in the frontal cortex and hippocampus were examined. Results were expressed as percent area of the neuropil occupied.
Analysis of Aβ plaque load
Amyloid plaque load was quantified as previously described8. Vibratome sections were incubated overnight with mouse monoclonal antibody 6E10 (1:600), which specifically recognizes human Aβ, followed by FITC-conjugated anti-mouse IgG. The FITC-labeled sections were imaged with the LSCM as described previously8. Digitized images were analyzed with NIH Image 1.43 to determine % area of neuropil occupied by Aβ immunoreactive deposits in hippocampus. Three immunolabeled sections were analyzed per mouse.
Determination of APP levels, APP products and Aβ-degrading enzymes
Levels of APP immunoreactivity were determined in brain homogenates by WB and in vibratome sections by ICC, as previously described25.
Hippocampal neuron cultures
Hippocampi from E18 mouse embryos were dissected free of meninges, minced, washed in HBSS and digested with 0.25% trypsin (Worthington) plus 0.05 mg/ml DNase I (Worthington) for 15 minutes at 37° C. Trypsinization was stopped with DMEM supplemented with 10% FBS and tissue was washed twice and subsequently dissociated by triturating 10 times with a flamed Pasteur pipet. Cells were passed through a 70 μm strainer (Corning) and plated at a density of 7 × 105 cells/well in poly-L-lysine (Sigma) coated 6-well plates in DMEM supplemented with 10% FBS. Four hours later, medium was removed and replaced with Neurobasal medium supplemented with 2% B27 (Invitrogen) and 100 units/ml penicillin and 100 μg/ml streptomycin. Subsequently, half volume of Neurobasal medium in each well was replaced twice a week. After one week, hippocampal neurons were treated with 50 ng/ml recombinant soluble type I or type III for 48 hours, respectively. For all treatments, cells were treated in triplicates and experiments were repeated a minimum of three times to ensure reproducibility.
How to cite this article: Xu, J. et al. Neuregulin 1 improves cognitive deficits and neuropathology in an Alzheimer's disease model. Sci. Rep. 6, 31692; doi: 10.1038/srep31692 (2016).
Goedert, M. & Spillantini, M. G. A century of Alzheimer’s disease. Science 314, 777–781 (2006).
Roberson, E. D. & Mucke, L. 100 years and counting: prospects for defeating Alzheimer’s disease. Science 314, 781–784 (2006).
Huang, Y. & Mucke, L. Alzheimer Mechanisms and Therapeutic Strategies. Cell 148, 1204–1222 (2012).
Lambracht-Washington, D. & Rosenberg, R. N. Advances in the development of vaccines for Alzheimer’s disease. Discov Med 15, 319–326 (2013).
Marciani, D. J. Alzheimer’s disease vaccine development: A new strategy focusing on immune modulation. Journal of Neuroimmunology 287, 54–63 (2015).
Estrada, L. D. & Soto, C. Disrupting beta-Amyloid Aggregation for Alzheimer Disease Treatment. Current Topics in Medicinal Chemistry 7, 115–126 (2007).
Singer, O. et al. Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat Neurosci 8, 1343–1349 (2005).
Marr, R. A. et al. Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. J Neurosci 23, 1992–1996 (2003).
Leissring, M. A. et al. Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology and premature death. Neuron 40, 1087–1093 (2003).
Mueller-Steiner, S. et al. Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer’s disease. Neuron 51, 703–714 (2006).
Falls, D. L. Neuregulins: functions, forms and signaling strategies. Exp Cell Res 284, 14–30 (2003).
Fleck, D. et al. Dual Cleavage of Neuregulin 1 Type III by BACE1 and ADAM17 Liberates Its EGF-Like Domain and Allows Paracrine Signaling. The Journal of Neuroscience 33, 7856–7869 (2013).
Mei, L. & Nave, K.-A. Neuregulin-ERBB Signaling in the Nervous System and Neuropsychiatric Diseases. Neuron 83, 27–49 (2014).
Go, R. C. et al. Neuregulin-1 polymorphism in late onset Alzheimer’s disease families with psychoses. Am J Med Genet B Neuropsychiatr Genet 139, 28–32 (2005).
Zhang, D. et al. Neuregulin-3 (NRG3): a novel neural tissue-enriched protein that binds and activates ErbB4. Proc Natl Acad Sci USA 94, 9562–9567 (1997).
Wang, K.-S. et al. NRG3 gene is associated with the risk and age at onset of Alzheimer disease. J Neural Transm 121, 183–192 (2014).
Chaudhury, A. R. et al. Neuregulin-1 and erbB4 immunoreactivity is associated with neuritic plaques in Alzheimer disease brain and in a transgenic model of Alzheimer disease. J Neuropathol Exp Neurol 62, 42–54 (2003).
Repetto, E., Yoon, I. S., Zheng, H. & Kang, D. E. Presenilin 1 regulates epidermal growth factor receptor turnover and signaling in the endosomal-lysosomal pathway. J Biol Chem 282, 31504–31516 (2007).
Zhang, Y. W. et al. Presenilin/gamma-secretase-dependent processing of beta-amyloid precursor protein regulates EGF receptor expression. Proc Natl Acad Sci USA 104, 10613–10618 (2007).
Rosen, K. M., Ford, B. D. & Querfurth, H. W. Downregulation and increased turnover of beta-amyloid precursor protein in skeletal muscle cultures by neuregulin-1. Exp Neurol 181, 170–180 (2003).
Guo, W. P., Wang, J., Li, R. X. & Peng, Y. W. Neuroprotective effects of neuregulin-1 in rat models of focal cerebral ischemia. Brain Res 1087, 180–185 (2006).
Di Segni, A., Shaharabani, E., Stein, R. & Pinkas-Kramarski, R. Neuregulins rescue PC12-ErbB-4 cells from cell death induced by beta-amyloid peptide: involvement of PI3K and PKC. J Mol Neurosci 26, 57–69 (2005).
Hsieh, H. et al. AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron 52, 831–843 (2006).
Li, B., Woo, R. S., Mei, L. & Malinow, R. The neuregulin-1 receptor erbB4 controls glutamatergic synapse maturation and plasticity. Neuron 54, 583–597 (2007).
Rockenstein, E., Mallory, M., Mante, M., Sisk, A. & Masliaha, E. Early formation of mature amyloid-beta protein deposits in a mutant APP transgenic model depends on levels of Abeta(1–42). J Neurosci Res 66, 573–582 (2001).
Morgan, D. In Methods of Behavior Analysis in Neuroscience Frontiers in Neuroscience (ed. J. J. Buccafusco ) (2009).
Iwata, N. et al. Metabolic regulation of brain Abeta by neprilysin. Science 292, 1550–1552 (2001).
Hirata, M. et al. Increased expression of neuregulin-1 in differentiating muscle satellite cells and in motoneurons during muscle regeneration. Acta Neuropathol 113, 451–459 (2007).
Broccolini, A. et al. Neprilysin participates in skeletal muscle regeneration and is accumulated in abnormal muscle fibres of inclusion body myositis. J Neurochem 96, 777–789 (2006).
Pardossi-Piquard, R. et al. Presenilin-dependent transcriptional control of the Abeta-degrading enzyme neprilysin by intracellular domains of beta APP and APLP. Neuron 46, 541–554 (2005).
Kwon, O. B., Longart, M., Vullhorst, D., Hoffman, D. A. & Buonanno, A. Neuregulin-1 reverses long-term potentiation at CA1 hippocampal synapses. J Neurosci 25, 9378–9383 (2005).
Chen, Y. J. et al. ErbB4 in parvalbumin-positive interneurons is critical for neuregulin 1 regulation of long-term potentiation. Proc Natl Acad Sci USA 107, 21818–21823 (2010).
Shamir, A. et al. The Importance of the NRG-1/ErbB4 Pathway for Synaptic Plasticity and Behaviors Associated with Psychiatric Disorders. The Journal of Neuroscience 32, 2988–2997 (2012).
Roysommuti, S., Carroll, S. L. & Wyss, J. M. Neuregulin-1beta modulates in vivo entorhinal-hippocampal synaptic transmission in adult rats. Neuroscience 121, 779–785 (2003).
Woo, R. S. et al. Neuregulin-1 enhances depolarization-induced GABA release. Neuron 54, 599–610 (2007).
Fisahn, A., Neddens, J., Yan, L. & Buonanno, A. Neuregulin-1 modulates hippocampal gamma oscillations: implications for schizophrenia. Cereb Cortex 19, 612–618 (2009).
Sanchez, P. E. et al. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer’s disease model. Proceedings of the National Academy of Sciences of the United States of America 109, E2895–2903 (2012).
Verret, L. et al. Inhibitory Interneuron Deficit Links Altered Network Activity and Cognitive Dysfunction in Alzheimer Model. Cell 149, 708–721 (2012).
Vullhorst, D. et al. Selective expression of ErbB4 in interneurons, but not pyramidal cells, of the rodent hippocampus. J Neurosci 29, 12255–12264 (2009).
Iwakura, Y. & Nawa, H. ErbB1-4-dependent EGF/neuregulin signals and their cross talk in the central nervous system: pathological implications in schizophrenia and Parkinson’s disease. Frontiers in Cellular Neuroscience 7, 4 (2013).
Agarwal, A. et al. Dysregulated Expression of Neuregulin-1 by Cortical Pyramidal Neurons Disrupts Synaptic Plasticity. Cell Reports 8, 1130–1145 (2014).
Yin, D.-M. et al. Reversal of Behavioral Deficits and Synaptic Dysfunction in Mice Overexpressing Neuregulin 1. Neuron 78, 644–657 (2013).
Rose, J. B. et al. Neuropeptide Y fragments derived from neprilysin processing are neuroprotective in a transgenic model of Alzheimer’s disease. The Journal of neuroscience: the official journal of the Society for Neuroscience 29, 1115–1125 (2009).
Spencer, B. et al. Peripheral Delivery of a CNS Targeted, Metalo-Protease Reduces Aβ Toxicity in a Mouse Model of Alzheimer’s Disease. PLoS ONE 6, e16575 (2011).
Liu, Y. et al. Expression of neprilysin in skeletal muscle reduces amyloid burden in a transgenic mouse model of Alzheimer disease. Molecular therapy: the journal of the American Society of Gene Therapy 17, 1381–1386 (2009).
Meilandt, W. J. et al. Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic Abeta oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice. The Journal of neuroscience: the official journal of the Society for Neuroscience 29, 1977–1986 (2009).
Saito, T. et al. Single App knock-in mouse models of Alzheimer’s disease. Nat Neurosci 17, 661–663 (2014).
Oddo, S. et al. Triple-transgenic model of Alzheimer’s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39, 409–421 (2003).
Middle, F. et al. No association between neuregulin 1 and psychotic symptoms in Alzheimer’s disease patients. J Alzheimers Dis 20, 561–567 (2010).
Kastin, A. J., Akerstrom, V. & Pan, W. Neuregulin-1-β1 enters brain and spinal cord by receptor-mediated transport. Journal of Neurochemistry 88, 965–970 (2004).
Carlsson, T. et al. Systemic administration of neuregulin-1β1 protects dopaminergic neurons in a mouse model of Parkinson’s disease. Journal of Neurochemistry 117, 1066–1074 (2011).
Spencer, B. J. & Verma, I. M. Targeted delivery of proteins across the blood-brain barrier. Proceedings of the National Academy of Sciences of the United States of America 104, 7594–7599 (2007).
Taveggia, C. et al. Neuregulin-1 type III determines the ensheathment fate of axons. Neuron 47, 681–694 (2005).
Rockenstein, E. et al. High beta-secretase activity elicits neurodegeneration in transgenic mice despite reductions in amyloid-beta levels: implications for the treatment of Alzheimer disease. J Biol Chem 280, 32957–32967 (2005).
Rockenstein, E. et al. Effects of Cerebrolysintrade mark on neurogenesis in an APP transgenic model of Alzheimer’s disease. Acta Neuropathol 113, 265–275 (2007).
This research was supported by grants from the NIH (HD034534, NS060833, NS072031, AG010435, CA014195, AG042985 and AG047669), the Clayton Foundation, the Schlink Foundation, the Gemcon Family Foundation and the Brown Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
The authors declare no competing financial interests.
Electronic supplementary material
About this article
Cite this article
Xu, J., de Winter, F., Farrokhi, C. et al. Neuregulin 1 improves cognitive deficits and neuropathology in an Alzheimer’s disease model. Sci Rep 6, 31692 (2016). https://doi.org/10.1038/srep31692
Neuregulin-1 regulates the conversion of M1/M2 microglia phenotype via ErbB4-dependent inhibition of the NF-κB pathway
Molecular Biology Reports (2022)
Is kallikrein-8 a blood biomarker for detecting amnestic mild cognitive impairment? Results of the population-based Heinz Nixdorf Recall study
Alzheimer's Research & Therapy (2021)